confirming the reduction of both NF-κB methylation and its subsequent activation upon drug treatment. These findings provide compelling grounds for considering Can and Clo as anti-PRMT5 cancer ...

Previous research from the Adli laboratory showed an abundance of PRMT5—an enzyme known for its role in regulating gene expression—in chemotherapy-resistant ovarian cancer. In the current ...

It’s been a busy week for a cancer drug target called PRMT5 that may play a role in treating a variety of solid tumors. Amgen on Friday presented preliminary results from its first study of an ...

Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase ...

Shares in Tango fell 26% to $3.81 in premarket trading. TNG908 is a MTA-cooperative PRMT5 inhibitor. In cells with MTAP deletion, a mutation found in 10% to 15% of solid tumors, the metabolite MTA ...

Schrödinger will also present preclinical data from its PRMT5-MTA program during a poster session on October 25. Schrödinger scientists have identified a novel series of selective, potent PRMT5 ...

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...

With the grant, the team looks to better understand one particular enzyme: protein arginine methyltransferase 5, or PRMT5. "Fifteen percent of all human cancers have a gene deletion that makes ...

confirming the reduction of both NF-κB methylation and its subsequent activation upon drug treatment. These findings provide compelling grounds for considering Can and Clo as anti-PRMT5 cancer ...